Effect of early initiation of evolocumab and Combination lipid-lowering agent (statin + ezetimibe) on lipid profiles changes in patients with acute coronary Syndrome undergoing percuTAneous coronaRy intervention: a prospective, randomized controlled trial (C-STAR trial)

Yonsei University Yongin Severance Hospital0 个研究点目标入组 102 人开始时间: 待定最近更新: 2022年11月28日

试验速览

暂无简介。

•(1) Over 19 years old
•(2) Patients who agreed to the research protocol and clinical follow-up survey plan, decided to participate in this study voluntarily, and gave written consent to the informed consent form.
•(3) Patients who underwent percutaneous coronary stenting for acute coronary syndrome

•? Patients who have previously taken statins,
•? Patients with active liver disease or patients with three times or more increase in AST or ALT
•? If you have an allergic or hypersensitivity reaction to Evorucumab, statin, or Ezetimib,
•? Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study
•? The remaining life expectancy is expected to be less than a year.
•? Subjects who visited the hospital due to psychogenic shock and are expected to be less likely to survive by medical judgment
•? Subjects participating in a randomized clinical trial of medical devices/pharmaceuticals

发起方

Yonsei University Yongin Severance Hospital